Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.

Expert review of molecular diagnostics - 1 Mar 2020

Michaelidou Kleita, Agelaki Sofia, Mavridis Konstantinos

Abstract excerpt

Introduction: The landscape of systemic treatment options for lung cancer has rapidly evolved with the emergence of immunomodulatory agents such as neutralizing antibodies targeting the programmed cell death protein 1 (PD-1) and its ligand (PD-L1). Another major breakthrough was the introduction of biomarkers, such as PD-L1 expression and tumor mutational burden (TMB), predicting response to immunotherapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Disease Susceptibility

Share to Immunologic Surveillance

Share to Immunomodulation

Share to Lung Neoplasms

Share to Microsatellite Instability

Source

Identifiers

PMID: 32000550
DOI: 10.1080/14737159.2020.1724785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.PMID 32000550Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

[Emerging biomarker for immunotherapy of non-small cell lung cancer: tumor mutation burden (TMB) and latest progress in related research field].Semantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read ↗

Precision medicine in non-small cell lung cancer: Current applications and future directions.Semantic proximity Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.Semantic proximity Read ↗

Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.